```html
Disorders in the immune system and lymphocyte function can lead to immune diseases or cancer. Our goal is to study the molecular mechanisms underlying immune-mediated diseases to enable personalized treatment in the future.
The Molecular Systems Immunology group aims to understand the regulation of the human immune system to predict, prevent, and treat immune-mediated disorders. We focus on the epigenetic and transcriptional regulation of T cells and the molecular mechanisms of diseases such as Type 1 Diabetes.
This project studies how novel long noncoding RNAs influence human T cell differentiation and their role in autoimmune diseases and cancer (Andrabi et al. Proc Natl Acad Sci U S A. 121:e2315363121, 2024 PMID: 38805281, Khan et al. Front. Immunol., 13: 856762, 2022 PMID: 35784351 and unpublished results).
In collaboration with Orion Pharma's Immuno-Oncology team, this project investigates the molecular basis of human T cell exhaustion in cancer (Brunell et al. Front Immunol 14:1151632, 2023 PMID: 37122741 and unpublished results). Experimental work will utilize single-cell genomics, mass cytometry, proteomics, and CRISPR-Cas9, along with computational tools.
The salary is determined by the collective agreement system of Finnish universities, ranging from 2440 to 2800 EUR/month. The position starts on October 1st, 2024 (or as agreed) and is initially for two years, with the possibility of 1-2 additional years for a doctoral researcher. There is a six-month trial period.
Please include a CV, full publication list, list of selected publications, and contact information for three references in your application.
For further information, please contact Prof. Riitta Lahesmaa at riitta.lahesmaa (at)utu.fi. Enquiries on the application procedure may be directed to HR Specialist Paula Luoma at paula.luoma(at)utu.fi. From August 7, 2024, to July 31, 2024, application enquiries will be answered by central HR services at hr-tuki(at)utu.fi.
Turku Bioscience Centre is a joint research institute of the University of Turku and Åbo Akademi University. Our mission is to promote high-quality research and training with state-of-the-art technology platforms and expertise in single-cell omics, NGS, epigenomics, proteomics, computational biology, and high-end cell imaging and cytometry.
Orion Immuno-Oncology (IO) Team, led by Dr. Anil Thotakura, is responsible for innovative drug discovery projects, identifying clinical unmet needs, and experimentally validating potential IO drug targets using advanced laboratories and technologies.
Turku Bioscience is an advanced core facility and research centre hosted jointly by the University of Turku and Åbo Akademi University. We aim to provide comprehensive service expertise to shorten the path from discovery to success for both academic and corporate research groups. We stay at the forefront of new technologies and facilitate interactions and joint projects between academia and industry.
The University of Turku is an inspiring and international academic community of 25,000 students and staff in Southwest Finland. We build a sustainable future with multidisciplinary research, education, and collaboration. Your work with us will have a significant impact and relevance in the changing world.
The application form cannot be saved as a draft. However, after submitting, you can return to edit your application via the link you receive by email until the application deadline.
You have 6 hours to complete your application before the timeout.